祥生医疗:股东计划减持公司股份不超过约336万股
Company Overview - Xiangsheng Medical's revenue composition for the year 2024 is 99.88% from the medical device industry and 0.12% from other businesses [1] Shareholder Activity - As of the announcement date, Mo Ruoli, the actual controller and chairman of Xiangsheng Medical, directly holds 26.46 million shares, accounting for 23.6% of the total share capital [3] - Mo Ruoli plans to reduce her holdings by up to 3% of the total share capital, which amounts to approximately 3.36 million shares, within three months after the announcement [3] - The planned reduction includes a maximum of 1% (approximately 1.12 million shares) through centralized bidding and 2% (approximately 2.24 million shares) through block trading [3]